Bifidobacterium infantis 35624
Selected indexed studies
- Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. (Curr Med Res Opin, 2017) [PMID:28166427]
- Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. (Rev Gastroenterol Disord, 2009) [PMID:19367213]
- Bifidobacterium infantis 35624 efficacy in patients with uncontrolled asthma: A randomized placebo-controlled trial. (Ann Allergy Asthma Immunol, 2022) [PMID:36089255]
_Worker-drafted node — pending editorial review._
Connections
Bifidobacterium infantis 35624 helps
Sources
- Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. (2017) pubmed
- Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. (2009) pubmed
- Bifidobacterium infantis 35624 efficacy in patients with uncontrolled asthma: A randomized placebo-controlled trial. (2022) pubmed
- Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. (2013) pubmed
- Fecal bacterial microbiota in constipated patients before and after eight weeks of daily Bifidobacterium infantis 35624 administration. (2023) pubmed
- The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. (2010) pubmed
- In Vivo Investigation of Supportive Immunotherapeutic Combination of Bifidobacterium infantis 35624 and Doxorubicin in Murine Breast Cancer. (2023) pubmed
- Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. (2013) pubmed
- Effects of Bifidobacterium infantis 35624 on post-inflammatory visceral hypersensitivity in the rat. (2011) pubmed
- Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. (2012) pubmed